Novel technology could significantly advance genomics field
New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.
List view / Grid view
Gene testing is a type of medical test that identifies changes in chromosomes, genes, or proteins.
New technology system of drug-based markers for the selection or counter-selection of genes may advance genetic screening methods.
Researchers discovered that glioblastoma cells rely on biotin distribution for growth, leading to possible future drug combinations.
A team have found that two DNA changes appear to predict acute lymphoblastic leukaemia, illuminating genetic understanding of the disease.
Scientists used a synthetic thyroid hormone in mice to regulate the TREM2 gene implicated in diseases such as Alzheimer’s and Parkinson’s.
Scientists have uncovered an important clue to the COVID-19-related multisystem inflammatory syndrome in children (MIS-C).
New insights into lung squamous cell carcinoma (LSCC) have emerged from a proteogenomic study, leading to the identification of potential drug targets.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Researchers used an experimental small molecule that helped restore the removal of damaged mitochondria from brain cells in a mouse model of Parkinson's.
US researchers have identified potential new treatment targets for Alzheimer’s disease, as well as existing drugs that could be used against these targets.
The use of genetic testing has had a positive impact on patient care, bringing abundant opportunities for diagnosis or predictions of future diagnoses. Pushpanathan Muthuirulan explains how the application of genetic screening can help to customise healthcare for individuals based on their unique genetic makeup.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry. However, characterisation of oligos, specifically by ion-pair reversed phase liquid chromatography (IPRPLC), can be quite challenging.
Therapeutic oligonucleotides represent a recent breakthrough in the pharmaceutical industry.
Silencing RNA, or siRNA, are short, double-stranded RNA molecules which are not only an important research tool in molecular biology, but also an emerging therapeutic modality.
Superficially porous particle technologies provide a reduced diffusion path in comparison with their fully porous counterparts minimising the resistance to mass transfer during chromatographic separation.